{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:37:34Z","timestamp":1778726254068,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Aid for Scientific Research"},{"name":"School of Health Sciences, Faculty of Medicine, Tottori University"},{"name":"JSPS KAKENHI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00198-023-06816-5","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T16:01:36Z","timestamp":1686240096000},"page":"1703-1709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Urinary pentosidine level is associated with the risk of fracture in community-dwelling older adults: a prospective observational study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-1095","authenticated-orcid":false,"given":"Hiroshi","family":"Hagino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"6816_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention DaT","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention DaT (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"6816_CR2","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/jbmr.3124","volume":"32","author":"P Martineau","year":"2017","unstructured":"Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D, Kanis JA (2017) Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD Cohort. J Bone Miner Res 32:1568\u20131574","journal-title":"J Bone Miner Res"},{"key":"6816_CR3","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1002\/jbmr.4449","volume":"36","author":"WH Cheung","year":"2021","unstructured":"Cheung WH, Hung VW, Cheuk KY et al (2021) Best performance parameters of HR-pQCT to predict fragility fracture: systematic review and meta-analysis. J Bone Miner Res 36:2381\u20132398","journal-title":"J Bone Miner Res"},{"key":"6816_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00223-015-9985-5","volume":"97","author":"M Saito","year":"2015","unstructured":"Saito M, Marumo K (2015) Effects of collagen crosslinking on bone material properties in health and disease. Calcif Tissue Int 97:242\u2013261","journal-title":"Calcif Tissue Int"},{"key":"6816_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00198-009-1066-z","volume":"21","author":"M Saito","year":"2010","unstructured":"Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195\u2013214","journal-title":"Osteoporos Int"},{"key":"6816_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3177\/jnsv.65.526","volume":"65","author":"S Kashiwabara","year":"2019","unstructured":"Kashiwabara S, Hosoe H, Ohno R, Nagai R, Shiraki M (2019) Development and evaluation of novel ELISA for determination of urinary pentosidine. J Nutr Sci Vitaminol 65:526\u2013533","journal-title":"J Nutr Sci Vitaminol"},{"key":"6816_CR7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12891-021-04279-5","volume":"22","author":"K Moriwaki","year":"2021","unstructured":"Moriwaki K, Matsumoto H, Tanimura C, Osaki M, Nagashima H, Hagino H (2021) Urinary pentosidine level is associated with grip strength and gait speed in community-dwelling adults: a cross-sectional study. BMC Musculoskelet Disord 22:392","journal-title":"BMC Musculoskelet Disord"},{"key":"6816_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12891-019-2650-9","volume":"20","author":"K Moriwaki","year":"2019","unstructured":"Moriwaki K, Matsumoto H, Tanishima S, Tanimura C, Osaki M, Nagashima H, Hagino H (2019) Association of serum bone- and muscle-derived factors with age, sex, body composition, and physical function in community-dwelling middle-aged and elderly adults: a cross-sectional study. BMC Musculoskelet Disord 20:276","journal-title":"BMC Musculoskelet Disord"},{"key":"6816_CR9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00198-020-05447-4","volume":"31","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto H, Tanimura C, Kushida D, Osaka H, Kawabata Y, Hagino H (2020) FRAX score and recent fall history predict the incidence for sarcopenia in community-dwelling older adults: a prospective cohort study. Osteoporos Int 31:1985\u20131994","journal-title":"Osteoporos Int"},{"key":"6816_CR10","doi-asserted-by":"crossref","unstructured":"Matsumoto H, Hagino H, Sageshima H, Osaki M, Tanishima SCT (2015) Diagnosis of knee osteoarthritis and gait variability increases risk of falling for osteoporotic older adults: The GAINA study. Osteoporos Sarcopenia 1:46\u201352","DOI":"10.1016\/j.afos.2015.07.003"},{"key":"6816_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/diagnostics10040178","volume":"10","author":"S Subramaniam","year":"2020","unstructured":"Subramaniam S, Chan CY, Soelaiman IN, Mohamed N, Muhammad N, Ahmad F, Ng PY, Jamil NA, Aziz NA, Chin KY (2020) The performance of a calcaneal quantitative ultrasound device, CM-200, in stratifying osteoporosis risk among Malaysian population aged 40 years and above. Diagnostics (Basel) 10:178","journal-title":"Diagnostics (Basel)"},{"key":"6816_CR12","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00774-019-01017-9","volume":"37","author":"M Shiraki","year":"2019","unstructured":"Shiraki M, Kashiwabara S, Imai T, Tanaka S, Saito M (2019) The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women. J Bone Miner Metab 37:1067\u20131074","journal-title":"J Bone Miner Metab"},{"key":"6816_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/jc.2017-00929","volume":"103","author":"J Tamaki","year":"2018","unstructured":"Tamaki J, Kouda K, Fujita Y, Iki M, Yura A, Miura M, Sato Y, Okamoto N, Kurumatani N (2018) Ratio of endogenous secretory receptor for advanced glycation end products to pentosidine predicts fractures in men. J Clin Endocrinol Metab 103:85\u201394","journal-title":"J Clin Endocrinol Metab"},{"key":"6816_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397","journal-title":"Osteoporos Int"},{"key":"6816_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00726-011-1180-z","volume":"44","author":"M Nakano","year":"2013","unstructured":"Nakano M, Kubota M, Owada S, Nagai R (2013) The pentosidine concentration in human blood specimens is affected by heating. Amino Acids 44:1451\u20131456","journal-title":"Amino Acids"},{"key":"6816_CR16","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/jbmr.467","volume":"26","author":"S Tanaka","year":"2011","unstructured":"Tanaka S, Kuroda T, Saito M, Shiraki M (2011) Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal women. J Bone Miner Res 26:2778\u20132784","journal-title":"J Bone Miner Res"},{"key":"6816_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00198-009-0939-5","volume":"21","author":"E Gineyts","year":"2010","unstructured":"Gineyts E, Munoz F, Bertholon C, Sornay-Rendu E, Chapurlat R (2010) Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study. Osteoporos Int 21:243\u2013250","journal-title":"Osteoporos Int"},{"key":"6816_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00774-021-01208-3","volume":"39","author":"H Hagino","year":"2021","unstructured":"Hagino H, Uemura Y, Mori S, Sone T, Ohta H, Nakamura T (2021) Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study. J Bone Miner Metab 39:668\u2013677","journal-title":"J Bone Miner Metab"},{"key":"6816_CR19","doi-asserted-by":"publisher","first-page":"e10673","DOI":"10.1002\/jbm4.10673","volume":"6","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Saito M, Hagino H et al (2022) Association of urinary pentosidine levels with the risk of fractures in patients with severe osteoporosis: the Japanese Osteoporosis Intervention Trial-05 ( JOINT-05). JBMR Plus 6:e10673","journal-title":"JBMR Plus"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T07:02:17Z","timestamp":1695193337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6816"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06816-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HH received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. HN received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Johnson & Johnson K.K., Kyocera Corp., Medtronic, NuVasive Inc., Nippon Zoki Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Teijin Nakashima Medical Co., Ltd., and Kaken Pharmaceutical Co., Ltd.KM, TW, MO, and HM declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}